Deerfield Management Company, L.P. and affiliated entities filed an amended Schedule 13G with the SEC on November 13, 2026, disclosing beneficial ownership of 3,138,167 shares of common stock in BridgeBio Oncology Therapeutics, Inc. as of September 30, 2026.

Key Highlights

  • Total beneficial ownership: Deerfield Management Company, L.P. and James E. Flynn each reported beneficial ownership of 3,138,167 shares, representing 3.91% of the class.
  • Split across two funds: Deerfield Partners, L.P. holds 1,569,083 shares and Deerfield Private Design Fund V, L.P. holds 1,569,084 shares, according to the filing.
  • No sole voting or dispositive power: All reporting persons disclosed 0 shares with sole voting power and 0 shares with sole dispositive power.
  • Shared power only: All 3,138,167 shares attributed to Deerfield Management Company, L.P. and James E. Flynn are held with shared voting and shared dispositive power.
  • Ownership threshold: The filing states this represents ownership of 5 percent or less of the class.
  • Triggering event date: The date of the event requiring the filing is listed as September 30, 2026.

Deerfield's Amended 13G Position in BridgeBio Oncology Therapeutics

According to the amended Schedule 13G (Amendment No. 1), six reporting persons affiliated with Deerfield disclosed holdings in BridgeBio Oncology Therapeutics, Inc., whose common stock carries CUSIP number 107924102. The filing identifies the issuer's principal executive offices at 256 E. Grand Avenue, Suite 104, South San Francisco, CA 94080. All reporting persons are organized as Delaware limited partnerships, with the exception of James E. Flynn, who is identified as a United States citizen.

The filing states that Deerfield Management Company, L.P. serves as the investment adviser to both Deerfield Partners, L.P. and Deerfield Private Design Fund V, L.P. Deerfield Mgmt, L.P. is disclosed as the general partner of Deerfield Partners, L.P., while Deerfield Mgmt V, L.P. is the general partner of Deerfield Private Design Fund V, L.P. As a result, Deerfield Management Company, L.P. and James E. Flynn each report aggregate beneficial ownership of 3,138,167 shares, combining the two fund positions of 1,569,083 and 1,569,084 shares, respectively. Each represents 3.91% of the class, according to the filing.

The filing notes that all reporting persons hold zero shares with sole voting or sole dispositive power. All reported shares are held exclusively with shared voting and shared dispositive power. The filing further confirms this represents ownership of 5 percent or less of the class. All parties are addressed at 345 Park Avenue South, 12th Floor, New York, NY 10010, as listed in the document.

What Was Disclosed

Deerfield Management Company, L.P. and five affiliated entities, including James E. Flynn, filed an amended Schedule 13G disclosing aggregate beneficial ownership of 3,138,167 shares, or 3.91%, of BridgeBio Oncology Therapeutics, Inc. common stock as of September 30, 2026.